Shyam Natarajan

Cofounder, Avenda Health

Search every verified Shyam Natarajan interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Shyam Natarajan, cofounder and CEO of Avenda Health, discussed the company's work in prostate cancer treatment and its path to commercialization in recent podcast and panel appearances. In an August 2025 episode of the Wealthing Podcast, he described Avenda Health's focus on precision medicine, machine learning, and image-guided therapies, and noted that the company's diagnostic tool is contracted with several large hospitals and clinics, with patients able to access it through the company's website. He also recounted declining term sheets from investors at multiple funding stages, stating that he and his team made those decisions because they were not aligned on strategy, particularly regarding reimbursement and market access, which he said are important for a healthcare company to deliver long-term value to patients. In a March 2021 UCLA MedTech case study, Natarajan explained that Avenda Health uses AI to map individual patients' prostate cancer features and applies machine learning to underutilized clinical data to inform treatment decisions for urologists. He said the company engaged with the FDA for about six or seven years before receiving approval, working with the agency early on to align on its approach. He also credited UCLA's involvement in the company's early development and advised that full-time commitment is necessary for founders pursuing a technology they believe in.